Iterion Therapeutics Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$7.1M
- Investors
-
12
Iterion Therapeutics General Information
Description
Developer of novel targeted cancer therapeutics and a first-in-class small molecule inhibitor designed to treat advanced hepatocellular carcinoma and other Wnt-driven tumors for patients globally. The company utilizes its proprietary lead product, Tegavivint, to selectively degrade nuclear β-catenin and target TBL1 without the toxicities associated with traditional Wnt inhibitors, enabling oncology researchers, clinicians, and pharmaceutical partners to advance clinical trials, provide targeted therapies for previously undruggable cancer pathways, and improve durable disease control in heavily pre-treated oncology patients.
Contact Information
Website
www.iteriontherapeutics.comCorporate Office
- 7255 Helix Park Avenue
- Houston, TX 77030
- United States
Corporate Office
- 7255 Helix Park Avenue
- Houston, TX 77030
- United States
Iterion Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Grant | 19-Nov-2025 | $7.1M | Completed | Clinical Trials - Phase 2 | ||
| 11. Grant | 16-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 10. Later Stage VC (Series B1) | 16-Feb-2021 | Completed | Clinical Trials - Phase 2 | |||
| 9. Debt - PPP | 11-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series B) | 05-Dec-2018 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series A1) | 18-Dec-2017 | Completed | Startup | |||
| 6. Accelerator/Incubator | 02-Mar-2016 | Completed | Startup | |||
| 5. Early Stage VC (Series A) | 18-Jun-2015 | Completed | Startup | |||
| 4. Angel (individual) | 07-Jul-2014 | $500K | $775K | Completed | Startup | |
| 3. Grant | 19-Feb-2014 | $15.9M | $275K | Completed | Startup |
Iterion Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A2 | 5,236,054 | $0.001000 | 8% | $0.46 | $0.46 | 1x | $0.46 | 8.27% |
| Series A1 | 4,369,655 | $0.001000 | 8% | $0.38 | $0.38 | 1x | $0.38 | 6.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Iterion Therapeutics Comparisons
Industry
Financing
Details
Iterion Therapeutics Competitors (85)
One of Iterion Therapeutics’s 85 competitors is Dauntless Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dauntless Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| PDX Pharmaceuticals | Venture Capital-Backed | Portland, OR | ||||
| Apollomics | Formerly VC-backed | Foster City, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Iterion Therapeutics Signals
Iterion Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Clarevia Ventures | Venture Capital | Minority | ||
| Green Park & Golf Ventures | Venture Capital | Minority | ||
| Lumira Ventures | Venture Capital | Minority | ||
| Portal Innovations | Venture Capital | Minority | ||
| Viva BioInnovator | Accelerator/Incubator | Minority |
Iterion Therapeutics FAQs
-
When was Iterion Therapeutics founded?
Iterion Therapeutics was founded in 2010.
-
Where is Iterion Therapeutics headquartered?
Iterion Therapeutics is headquartered in Houston, TX.
-
What is the size of Iterion Therapeutics?
Iterion Therapeutics has 16 total employees.
-
What industry is Iterion Therapeutics in?
Iterion Therapeutics’s primary industry is Drug Discovery.
-
Is Iterion Therapeutics a private or public company?
Iterion Therapeutics is a Private company.
-
What is Iterion Therapeutics’s current revenue?
The current revenue for Iterion Therapeutics is .
-
How much funding has Iterion Therapeutics raised over time?
Iterion Therapeutics has raised $27.2M.
-
Who are Iterion Therapeutics’s investors?
Clarevia Ventures, Green Park & Golf Ventures, Lumira Ventures, Portal Innovations, and Viva BioInnovator are 5 of 12 investors who have invested in Iterion Therapeutics.
-
Who are Iterion Therapeutics’s competitors?
Dauntless Pharmaceuticals, Compass Therapeutics, PDX Pharmaceuticals, Apollomics, and Adaptimmune Therapeutics are some of the 85 competitors of Iterion Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process